| Name | BAX Inhibiting Peptide V5 |
|---|---|
| Synonyms |
L-Valyl-L-prolyl-L-methionyl-L-leucyl-L-lysine
Bax inhibitor peptide V5 |
| Description | Bax inhibitor peptide V5 is a Bax-mediated apoptosis inhibitor, used for cancer treatment. |
|---|---|
| Related Catalog | |
| Target |
Bax |
| In Vitro | Bax inhibitor peptide V5 (0-50 μM) reduces cell death in STF-cMyc cells but not in SW620 or NCI-H23 cells. BIPV5 does not result in any significant effect on cell cycle arrest at the G2/M phase[1]. V5 treatment upregulates expression of anti-apoptotic proteins Bcl-2 and XIAP by more than 3- and 11-fold and downregulates expression of apoptosis-inducing proteins Bax, Bad, and nuclear factor-κB-p65 by 10, 30, and nearly 50%, respectively[2]. |
| In Vivo | V5 (100 μM) significantly improves islet function following isolation and improves islet graft function following transplantation in mice model[2]. |
| Cell Assay | Cells (2.5×104 cells/mL) are grown in 96-well plates in a final volume of 100 μL/well. After 24 h, cells are incubated with small molecules or vehicle (DMSO) for 48-96 h prior to harvest. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole (MTT) reagent (0.5 mg/mL), is added to each well during the final 2 h, and absorbance is measured. Cell growth is calculated as the ratio of absorbance obtained upon compound treatment to that obtained with vehicle (DMSO) treatment. |
| References |
| Molecular Formula | C27H50N6O6S |
|---|---|
| Molecular Weight | 586.78700 |
| Exact Mass | 586.35100 |
| PSA | 232.72000 |
| LogP | 4.28730 |
| Storage condition | -20°C |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |